Bone marrow

FibroGen Appoints Deyaa Adib, M.D. as Chief Medical Officer

Retrieved on: 
Monday, March 11, 2024
Therapy, Breast cancer, SAN, Pharmacology, ARIAD Pharmaceuticals, Biotechnology, Baxalta, Bone marrow, Drug development, Prostate, Acute leukemia, Acting, Stomach, Sanofi, Oxaliplatin, Astellas Pharma, Patient, Oncology, Qasr El Eyni Hospital, Stromal cell, Pancreatic cancer, IND, Head, Colorectal cancer, Cancer, Prostate cancer, Medical imaging

SAN FRANCISCO, March 11, 2024 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced the appointment of Deyaa Adib, M.D., an executive leader with almost three decades of oncology development experience, as Senior Vice President & Chief Medical Officer to oversee all global clinical development activities.

Key Points: 
  • SAN FRANCISCO, March 11, 2024 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced the appointment of Deyaa Adib, M.D., an executive leader with almost three decades of oncology development experience, as Senior Vice President & Chief Medical Officer to oversee all global clinical development activities.
  • “Deyaa’s leadership and expertise in oncology research and clinical development, particularly in bringing oncology therapeutics to market, will be key to accelerating our oncology pipeline and bringing novel cancer therapies to patients in need,” said Thane Wettig, Chief Executive Officer of FibroGen.
  • “We will benefit immensely from Deyaa’s broad and deep experience in oncology drug development, including his experiences in both pancreatic and prostate cancers.”
    “I am excited to join FibroGen and lead the clinical development organization at this important time for our company,” commented Deyaa Adib, M.D., Chief Medical Officer of FibroGen.
  • Prior to joining FibroGen, he was the Chief Medical Officer of Triumvira Immunologics Inc. where he led the transition of two novel cell therapy programs into clinical development.

NMDP Awards 25th Annual ‘Amy Scholars’ Grant, Furthering Post-Transplant Research

Retrieved on: 
Wednesday, March 6, 2024
Bone marrow, Senior, Doctor of Philosophy, HCT, Research, Hematology, Graft-versus-host disease, Physician, Partnership, Data, University, Risk assessment, NMDP, Nursing, Patient, Disease, McGinn, DRS, Health equity, Laboratory, Buchbinder, Wilfrid Sellars, Pharmaceutical industry

Cieri and Sacirbegovic in their research efforts to improve the lives of those battling blood cancers and blood disorders.

Key Points: 
  • Cieri and Sacirbegovic in their research efforts to improve the lives of those battling blood cancers and blood disorders.
  • We are especially grateful to the Moore family, who generously funded the Amy Scholars Research Program in 2024,” said Joy King, Chief Advancement Officer, NMDP, and Executive Director, NMDP.
  • Since 1998, NMDP has invested more than $12 million, funding 51 early-career investigators and helping them develop research portfolios and establish their laboratories.
  • “For years, we have supported groundbreaking research by collaborating with an extensive network of physicians and scientists in impacting outcomes.

Bionano Reports Fourth Quarter and Full-Year 2023 Results and Provides Revenue Outlook for 2024

Retrieved on: 
Tuesday, March 5, 2024
SAN, Doctor of Philosophy, Research, FDA, Data collection, Growth, Overalls, Sale, Genomics, NGS, DSM-IV codes, Standard of care, IRB, Bone marrow, GAAP, Medicare, First Step, Genome, Data analysis, Symposium, OGM, Met, Publication, Comment, SOC, DNA, Cancer, Workflow, Video game

Total revenue for the fourth quarter of 2023 was $10.7 million, an increase of 30% compared to the fourth quarter of 2022.

Key Points: 
  • Total revenue for the fourth quarter of 2023 was $10.7 million, an increase of 30% compared to the fourth quarter of 2022.
  • GAAP gross margin for the fourth quarter of 2023 was 23%, which was slightly higher than the 22% GAAP gross margin reported for the fourth quarter of 2022.
  • Fourth quarter 2023 GAAP operating expense was $27.4 million, compared to $39.3 million in the fourth quarter of 2022.
  • Fourth quarter 2023 non-GAAP operating expense was $27.3 million, compared to $30.6 million in the fourth quarter of 2022.

A.I. Supercomputer Market Projected To Reach $3.3 Billion By 2028 with Significant Growth Expected

Retrieved on: 
Monday, March 4, 2024
Restaurant, FEMA, News, Growth, Fraud, NOW, Climate change, Human, Bone marrow, IRS, Organization, Leukemia, Disaster, OTCQB, Algorithm, Nvidia, Avant, Business development, Enterprise, ServiceNow, Cloud computing, Machine learning, Partnership, Drug discovery, Macular degeneration, Internal Revenue Service, Artificial intelligence, Research, Lymphoma, CFO, PALM, USD, Hugging Face, AI, Heel, Entrepreneurship, Multiple sclerosis, Patient, Medicine, SoundHound, Hand, Medical device

A report from MarketsAndMarkets said that the AI supercomputer market is projected to grow from USD $1.2 billion in 2023 and is expected to reach USD $3.3 billion by 2028, growing at a CAGR of 22.0% from 2023 to 2028.

Key Points: 
  • A report from MarketsAndMarkets said that the AI supercomputer market is projected to grow from USD $1.2 billion in 2023 and is expected to reach USD $3.3 billion by 2028, growing at a CAGR of 22.0% from 2023 to 2028.
  • The report said: “The Government segment in the AI supercomputer market for application is expected to hold the largest market size during the forecast period in the AI supercomputer market.
  • Moreover, AI supercomputers are also being used to coordinate disaster relief efforts and provide assistance to victims of disasters.
  • AI supercomputers process vast datasets in real time, providing valuable insights into customer behavior, market trends, and operational efficiency.

ImpactLife salutes longtime platelet donors on reaching major milestones

Retrieved on: 
Sunday, March 3, 2024
Collection, Bone marrow, Blood, Transplant, Army, Life, Health, Thrombocytopenia, Patient, Plateletpheresis, Bleeding, Trauma, Donor, Cancer, Medical device

Davenport, Iowa, March 03, 2024 (GLOBE NEWSWIRE) -- A pair of longtime platelet donors have reached significant donor milestones with ImpactLife, highlighting the importance of consistent donation patterns to meeting patient needs.

Key Points: 
  • Davenport, Iowa, March 03, 2024 (GLOBE NEWSWIRE) -- A pair of longtime platelet donors have reached significant donor milestones with ImpactLife, highlighting the importance of consistent donation patterns to meeting patient needs.
  • The nonprofit blood provider based in Davenport, Iowa, has approximately 6000 active platelet donors who have made at least one donation in the last two years.
  • He continued as a whole blood donor after returning from Vietnam, and recalls being asked to give platelet donation a try.
  • To help grow its base of platelet donors, ImpactLife is offering a $50 electronic gift card for those who donate platelets for the first or second time with ImpactLife.

SELLAS Life Sciences Delivers Oral Presentation of SLS009 Phase 1 Data for Acute Myeloid Leukemia Patients at 2024 European School of Haematology (ESH) Conference

Retrieved on: 
Friday, March 1, 2024
PD, Bone marrow, AML, Toxicity, Aes, MD, Therapeutic index, European School, Conference, Safety, Biomarker, MYC, Pharmacokinetics, Patient, MRD, Survival, MD Anderson Cancer Center, Acute myeloid leukemia, CDK9, SLS, Pharmaceutical industry

NEW YORK, March 01, 2024 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS” or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today announced the delivery of an oral presentation of data for the cohort of patients with acute myeloid leukemia (AML) from the Phase 1 dose-escalation study of SLS009 (formerly GFH009) by Dr. Tapan Kadia, Professor at MD Anderson Cancer Center and the study’s primary investigator, at the 2024 European School of Haematology Acute Leukaemias (ESH) Conference: How to Diagnose and Treat Acute Leukaemias, taking place March 1-3, 2024, in Stockholm, Sweden.

Key Points: 
  • Positive topline data for the heavily pretreated AML patients showed evidence of anti-tumor activity increasing with higher dose levels and no significant safety issues.
  • The CR lasted eight months with the patient achieving one year survival at the latest assessment.
  • Strong inhibitory activity against key biomarkers with a dose-proportional response and universal decrease of MYC and MCL-1 in evaluable patients.
  • “Its potential strong synergy with the standard regimen of venetoclax and hypomethylating agents could open up new avenues in the treatment of acute myeloid leukemia.

Cullinan Oncology Announces U.S. FDA Clearance of Investigational New Drug Application for Novel MICA/B Antibody, CLN-619, for Relapsed/Refractory Multiple Myeloma

Retrieved on: 
Friday, March 1, 2024
CGEM, Escape Room, FDA, Food, SITC, MBA, MICA, Bone marrow, Immunoglobulin G, MICB, Malignancy, Patient, MPH, Multiple myeloma, IND, Trial of the century, Vaccine

CAMBRIDGE, Mass., March 01, 2024 (GLOBE NEWSWIRE) -- Cullinan Oncology, Inc. (Nasdaq: CGEM), a biopharmaceutical company focused on modality-agnostic targeted oncology therapies, today announced the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for CLN-619 in relapsed/refractory multiple myeloma. CLN-619 is a potential first-in-class humanized IgG1 monoclonal antibody that binds to stress-induced ligands, MICA and MICB, which are expressed on a wide variety of solid tumors and hematologic malignancies. The company will commence a Phase 1 dose-escalation and dose-expansion trial of CLN-619.

Key Points: 
  • The company will commence a Phase 1 dose-escalation and dose-expansion trial of CLN-619.
  • “Multiple myeloma remains incurable, and most patients experience sequential relapses.
  • The response to treatment is typically shorter with each relapse, so novel treatments are still needed,” said Jeffrey Jones, MD, MPH, MBA, Chief Medical Officer, Cullinan Oncology.
  • “Multiple myeloma is another example of a malignancy where MICA/B shedding from tumor cells allows for immune evasion.

Sana Biotechnology Reports Fourth Quarter and Full Year 2023 Financial Results and Business Updates

Retrieved on: 
Thursday, February 29, 2024
Neoplasm, CD47, VIVID, CD19, Exercise, Science Translational Medicine, Bone marrow, Lymphoid leukemia, Lupus nephritis, CTA, Biotechnology, Escape Room, Research and development, GLEAM, ANCA, GAAP, Sana, Insulin, Development, Immune system, Regeneration, ASH, CD22, AACR, B cell, Safety, Immunosuppression, Diabetes, Patent, IND, Insurance, Nature Biotechnology, NHL, Cancer, CLL, Contingency, Cell, NHP, Organoid, Autoimmunity, Administration, Cell Stem Cell, Patient, HIP, Nature Communications, ISSCR, C-peptide, Vaccine

The Investigational New Drug Application (IND) cleared in 4Q 2023, and Sana expects to share initial data in 2024.

Key Points: 
  • The Investigational New Drug Application (IND) cleared in 4Q 2023, and Sana expects to share initial data in 2024.
  • The Clinical Trial Application (CTA) cleared in 4Q 2023, and Sana expects initial data to be shared in the first half of 2024.
  • Non-GAAP research and development expense in 2023 excludes an expense related to the impairment of certain lab equipment and leasehold improvements, primarily due to the portfolio prioritization in the fourth quarter of 2023.
  • A discussion of non-GAAP measures, including a reconciliation of GAAP and non-GAAP measures, is presented below under “Non-GAAP Financial Measures.”

Inhibikase Therapeutics Announces Full Outcomes of its Pre-NDA Meeting with the FDA for IkT-001Pro

Retrieved on: 
Wednesday, February 28, 2024
Therapy, Division, Blood, Mesylate, FDA, Physician, Bone marrow, Food, Approximation error, Risk, Imatinib, Parkinson's disease, Patient, Trial of the century, NDA

“With the full meeting minutes from the FDA Review Team in hand, we are confident in our approach as we develop the NDA for IkT-001Pro,” said Dr. Milton Werner, President and Chief Executive Officer of Inhibikase.

Key Points: 
  • “With the full meeting minutes from the FDA Review Team in hand, we are confident in our approach as we develop the NDA for IkT-001Pro,” said Dr. Milton Werner, President and Chief Executive Officer of Inhibikase.
  • Further, we are not restricted from use in children nor restricted to just blood cancer-related approved indications.
  • This opens-up the opportunity to seek all 11 approved indications for IkT-001Pro that were previously approved for imatinib mesylate.
  • All other elements of the pre-NDA meeting remain unchanged from those reported on February 7, 2024.

International Myeloma Foundation (IMF) Launches #MyelomaActionMonth for 2024 March Myeloma Action Month

Retrieved on: 
Tuesday, February 27, 2024
Wall, Research, Doctor of Philosophy, RN, MSN, Courage, Quality of life, Friends, FAAN, Hope, ACTION, Empathy, Education, IMF, Human, Global Video, Bone marrow, Organization, Myeloma Canada, Patient, Family, Disease, Diagnosis, Movement, LIVE, Cryptocurrency

“This March Myeloma Action Month stands as a testament to the collective power of ACTION.

Key Points: 
  • “This March Myeloma Action Month stands as a testament to the collective power of ACTION.
  • Myeloma Action Month isn't just about awareness; it's about empowering ourselves, our loved ones, and the global community to fight back.
  • “This March, let us all take action for Myeloma Action Month and shine a bright light on the collective strength of our global myeloma community.
  • Join the movement and help the IMF spread myeloma awareness on a global scale this 2024 March Myeloma Action Month!